Literature DB >> 1495835

[Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].

P Chavanet1, N Charlier, A Brenet, A Goux, E Muggéo, D Caillot, O Casasnovas, J P Kistermann, A Waldner, H Portier.   

Abstract

Toxic effects limit the use of amphotericin B (AmB) for the treatment of systemic Candida infections. In vitro and in vivo toxicity can be substantially reduced by mixing AmB with a lipid emulsion used for parenteral nutrition, intralipid 20% (IL). This study was designed to evaluate the potential effects of IL on the activity of Amphotericin B against Candida. A clinical strain of Candida albicans was used. AmB deoxycholate (Fungizone) was reconstituted in a 5% glucoce solution (AmB-G5), in 3 mg/ml IL (AmB-IL3) or in 1.5 mg/ml IL (AmB-IL 1.5). Minimum inhibitory concentrations and minimum lethal concentrations were 0.4 mg/l and 2.5 mg/l, respectively, with AmB-G5, 0.1 mg/l and 1 mg/l with AmB-IL3, and 0.24 mg/l and 1 mg/l with AmB-IL 1.5. In vitro killing curves with 0.1 mg/l, 0.25 mg/l, and 2.5 mg/l AmB were determined with the following results: 1) with 0.1 and 0.25 mg/l AmB, fungicidal activity was seen with AmB-IL3 and AmB-IL 1.5 but not with AmB-G5; 2) with 2.5 mg/l AmB, fungicidal activity was less marked with AmB-G5 (-1.7 log CFU/ml after 24 hours) than with AmB-IL3 and AmB-IL1.5 (-4.3 log CFU/ml and -4.2 log CFU/ml, respectively, after 24 hours; p less than 0.05). In rabbits given a single intravenous injection of 4 mg/kg AmB, analysis of infected subcutaneous fibrin clots detected measurable concentrations of AmB beyond the 24th-36th hour, with levels of 0.5 mg/l for AmB-G5 and 1 mg/l for the two AmB-IL preparations over a period of three days.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495835

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B.

Authors:  M A Moreno; P Frutos; M P Ballesteros
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.

Authors:  S Walker; S A Tailor; M Lee; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.

Authors:  A Ayestarán; R M López; J B Montoro; A Estíbalez; L Pou; A Julià; A López; B Pascual
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

Authors:  P Y Chavanet; I Garry; N Charlier; D Caillot; J P Kisterman; M D'Athis; H Portier
Journal:  BMJ       Date:  1992-10-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.